Source: Trial Site News

A group of Texas-based providers, including physicians, some highly published, recently published in the International Journal of Innovative Research in Medical Science results of a case series type of study involving a group of 320 COVID-19 patients deemed high risk—that is, over 50 years old with at least one comorbidity.

The group actually was able to add 549 cases more by the end of the study period, which was December, 2020. This group of physicians, part of a small but vocal and dedicated camp, declare that during the pandemic, the medical profession disappointed, turning into “watchful watchers” for the vast majority of COVID-19 cases—and especially those cases that fit the study patient cateogry—desperately needing care. 

The authors argue that in far too many cases, these at risk patients were acknowledged to have COVID-19, sent home, and told to return if symptoms worsened. Many people lost parents and grandparents due to this form of doctoring, which could be classified by one point of view as the active caring wing but yet by a mainstream as rogue. 

This study is observational in nature (e.g. isn’t a randomized controlled trial) for the practitioners that provided the care as well as the framework for studious review and analysis of associated data—and results for them that matter. Based on the results, it most certainly did for the patients as well.

Using a protocol of zinc, hydroxychloroquine or ivermectin and one antibiotic (azithromycin, doxycycline, ceftriaxone) in combination with inhaled budesonide and/or intramuscular dexamethasone, the doctors, including accomplished researchers, such as Dr. Peter McCullough who have presented on TrialSite Podcast,  sought to follow the Hippocratic oath and care for their COVID-19 patients—opting to take action and not passively stand by and do nothing.

They found a lot of misleading information circulating about, and ambulatory patients with some risk factors during the pandemic actually were facing great risk. While the introduction of emergency use monoclonal antibodies (Lilly and Regeneron) helped care for more of this class of patient, they still were not reaching enough patientstoo many were dying. 

The results of their observational, case seriesbased comparison study to the Cleveland Clinic COVID-19 hospitalization calculator as applied to four Texas counties where they practice—were notable. 

The early ambulatory treatment regimen was associated with an estimated 87.6% reduction in hospitalization and 74.9% reduction in death (p<0.0001).

The authors of this study have taken heat for doing what they signed up for doing as a doctor—following the Hippocratic oath and practicing medicine. 

But particularly at the onset of the pandemic, they discussed among themselves the confusion among even the most elite of research institutions, the lengthy and in some cases irrelevant research funded with in hundreds of millions of dollars juxtaposed to the tens of thousands that were dying—in the aggregate, over 560,000 have passed away due to COVID-19. 

Care for the Patient: An Important Priority

These healthcare providers were concerned that during the two study periods associated with this case series (April to September 2020 and September to December 2020) that doing nothing while vaccines were under development was not good medicine.

They felt they had a duty to look at studies around the world and find pathways that led to less death. While there are still no authorized drugs for ambulatory care (remdesivir requires hospitalization and monoclonal antibodies must be administered in clinical setting), and unfortunately no deemed conclusive randomized trials of multidrug therapy to help doctors, in this, and all serious medical conditions, the authors emphasize the historically significant and relevant role for empiric treatment in an attempt to reduce fatalities concluded the study authors. 

Thus, the doctors’ methodical oversight of a total of 869 patient cases with by comparison striking results. 

Could the outcomes here be the result of selection bias? That’s one of the common arguments to challenge this type of study.  But the argument here is not that the regimens included in this case series—-ivermectin and doxycycline for example—are established evidence based on this study. That’s not the point.

The authors, rather, in keeping to the Hippocratic oath, organized a study that would generate real world data and the clinical outcomes associated with an empiric multidrug regimen for confirmed COVID-19 patients presenting in the practices of the physicians in this part of Texas. 

Lead Research/Investigators

Related: Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

The story behind hydroxychloroquine and the Zelenko Protocol: safe pre-hospital treatments for Covid

Brazil: ‘To say that hydroxychloroquine and ivermectin kill is a fallacy’, says president of the Federal Council of Medicine

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »